miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 18, 2026

Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%?

View original at finance.yahoo.com
Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%? Daniel J. Englander, Director at Copart, Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Daniel J. Englander sold 80,000 shares of Copart common stock on July 13, 2026, for a transaction value of $2.2 million.

    60% confidence
  • Ursula Capital Partners distributed 40,000 shares to its limited partners on July 13, 2026, and Daniel J. Englander was excluded from this distribution.

    60% confidence
  • The shares were sold in multiple transactions at prices ranging from $27.50 to $27.66, with the reported price of $27.55 reflecting the weighted average of these executions.

    60% confidence
  • Daniel J. Englander holds no shares directly; his remaining interest consists of approximately 511,000 shares held indirectly through Ursula Capital Partners, representing a 0.0552% ownership stake in Copart.

    60% confidence
  • Copart operates as a global provider of online vehicle auctions with a market capitalization of $25.5 billion as of the July 14, 2026 market close, generating $4.6 billion in trailing twelve-month revenue and $1.6 billion in net income over the same period.

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%? — Source | Via News | es.VIA.NEWS